• News
  • SAN DIEGO
  • BioTech

Mast Therapeutics reports 2Q net loss

San Diego-based Mast Therapeutics Inc. (NYSE: MSTX) reported a second quarter net loss of $7.2 million, or $0.06 per share, compared to a net loss of $4.9 million, or $0.09 per share, for the same period in 2013.

The company also reported a net loss for the six months ending June 30, 2014 of $13.5 million, or $0.12 per share, compared to a net loss of $10.5 million, or $0.21 per share, for the same period in 2013.

The company had cash, cash equivalents and investment securities totaling $46.4 million as of June 30. Stockholders' equity amounted to $50.2 million as of June 30.

“This is an important time for Mast,” said Brian M. Culley, the company’s CEO. “We have an ongoing Phase 3 study in a rare disease with more than an 18-month head start on our nearest competitor.”

The company also has a Phase 2 study planned in heart failure and has funds to move these and our other programs toward major value inflection points, according to Culley.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Mast Therapeutics Inc.

Company Website

12390 El Camino Real Ste., 150
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MSTX
0.5
  -0.01  
- 1.96%
703,889,000
0.63
0.38

Mast Therapeutics Inc. Executive(s):

Brian Culley

  • Chief Executive Officer

Patrick Keran

  • Chief Operating Officer, President

Brandi Roberts

  • Chief Financial Officer